About This Reading Room

What Highlander Peptide is

Highlander Peptide is a reading room for the published research on two compounds studied in the context of longevity and cellular health: Epitalon and NAD+. It exists to make a frequently overstated, unevenly replicated, and commercially noisy literature legible — to tell a reader, in plain language and with citations, what each compound was actually studied for, in which species and model system, and how far that evidence honestly reaches.

The organizing frame is telomere and pineal geroprotection. Epitalon sits at the intersection of those two axes — proposed telomerase upregulation and pineal melatonin normalization. NAD+ sits at the metabolic axis of aging — the central cellular coenzyme whose age-related decline has generated the field's largest body of human trial evidence. Each compound has its own dedicated page; a comparison page lines them up on the dimensions that matter for reading research; and a single shared references list aggregates every source cited on the site.

The standard here is evidence quality at its actual grade. Where a claim is from cell culture, this room says cell culture. Where it is a mouse result, it says mouse result. Where the human data are observational without a placebo arm, it says so plainly. Where an independent replication now exists that didn't before, that is noted too — as a genuine advance, not minimized, but also not extrapolated beyond what it shows. The room does not cherry-pick favorable results or suppress inconvenient caveats; the caveats are the point.

How it is compiled

Three rules govern what lands in this room.

First, everything is anchored to peer-reviewed sources. Every research claim is tied to a numbered citation — PubMed-indexed journal articles and reviews, with DOIs and PubMed links — collected in full on the references page. Where a finding comes from a review rather than a primary study, the review is cited as such, and where the review's conclusions differ from the underlying papers, that distinction is noted.

Second, evidence is reported at its actual strength. Study doses are given in the species, route, and concentration in which they were used — for example, "1.0 ug/mouse subcutaneously in female SHR mice" — never scaled to humans or offered as a recommendation. Where the evidence is preclinical, originating from a single laboratory, or uses a different compound from the one being marketed (as with epithalamin versus Epitalon), the page says so directly. That precision is not hedging — it is the core purpose of the room.

Third, context is carried forward across pages. Because the same mechanisms — telomerase, sirtuins, CD38, melatonin — recur in both research areas, the compound pages cross-reference each other where the biology overlaps, so a reader can trace a mechanism across the two entries rather than treating each page as a silo.

What it is not

Highlander Peptide sells nothing, treats no one, and prescribes nothing. No compound or research chemical is sold, supplied, sourced, or brokered here, and there is no affiliate or referral tie to any vendor or IV-therapy provider. No clinician is on staff; nothing is diagnosed and nothing is prescribed. No dose, schedule, cycle length, or route of administration is recommended for any person — not even informally, and not by implication.

The compounds discussed here differ in regulatory status: Epitalon is a research chemical with no approved human use in major Western markets; NAD+ precursors are marketed as dietary supplements, with compounded injectable forms carrying additional regulatory and safety complexity. Neither fact makes either compound a medicine for any aging-related condition, and neither is presented here as one. Readers interested in any condition described in the underlying research should consult a licensed clinician working with regulated, evidence-based options. The aim of this room is accuracy about what the science says — nothing more, and nothing it pretends to be.